Capricor Therapeutics is trading 6.47% down at $6.16 in pre-market on October 15 amid broader risk-off pressure following hotter-than-expected U.S. inflation.
- The decline follows several declining sessions; no new company-specific announcement or earnings catalyst was identified for October 15.
- The latest available check, on October 14, also reported no new catalyst.
- Rising rates and investor caution have pressured biotech shares, while inflation concerns weighed on growth stocks and spilled into Asian markets.